What is Cytosorbents's market cap?

Cytosorbents (CTSO) has a market capitalization of $23.4M and trades on NASDAQ.

Who are Cytosorbents's competitors?

Cytosorbents's key competitors include Baxter International (Vantive), LivaNova PLC Ordinary Shares, TransMedics Group, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Cytosorbents partner with?

Cytosorbents's notable partners include Fresenius Medical Care AG, B. Braun Avitum AG, Terumo Cardiovascular Group, and others.

Where is Cytosorbents headquartered?

Cytosorbents is headquartered in United States of America and employs approximately 186 people. It has been publicly traded since 2005.

Cytosorbents

CTSO

CytoSorbents is a leader in blood purification technology focused on treating life-threatening conditions in intensive care and cardiac surgery.

Market cap

$23.38M-67.2%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$8.9MMiss by $536.0K EPS-$0.08Miss by $0.02

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$9.4M

EPS estimate-$0.05

Competitors

By market cap

Baxter International$11.6B-23.9%

LivaNova$4.5B+82.4%

Haemonetics$3.4B-5.6%

TransMedics Group, Inc.$2.5B-41.1%

LeMaitre Vascular$2.3B+24.8%

Cytosorbents$23.4M-63.7%

CalciMedica$15.0M-33.3%

Nuwellis, Inc.$265.5K-99.5%

By revenue growth

TransMedics Group, Inc.+30.2%

LeMaitre Vascular+13.3%

LivaNova+12.4%

Baxter International+5.1%

Haemonetics-2.0%

By net margin

TransMedics Group, Inc.27.04%+17.0pp

LeMaitre Vascular24.35%+4.4pp

Haemonetics13.31%—

Baxter International-9.7%-4.5pp

LivaNova-16.12%-22.5pp

Profile

CytoSorbents is a leader in blood purification technology focused on treating life-threatening conditions in intensive care and cardiac surgery. The company's proprietary platform utilizes biocompatible, highly porous polymer beads to actively remove toxic substances, such as cytokines and blood thinners, from blood and other bodily fluids. Its core value proposition lies in reducing lethal inflammation and surgical complications through extracorporeal therapies that integrate with existing hospital equipment.

Competitive position

A leader in cytokine adsorption and the only provider of approved therapies for the removal of specific blood thinners like ticagrelor and rivaroxaban in the EU.

GeographiesUnited States, European Union, Canada, Global

Customer segmentsAcute Care Hospitals, Specialized Surgical Centers, Veterinary Clinics

Business modelMedical Device Manufacturing, Direct Sales, Distributor-led Sales

SuppliersPolymer resin manufacturing, Medical-grade plastic components, Sterilization services

CustomersCritical care physicians, Cardiothoracic surgeons, Hospital procurement departments, Veterinarians

CountryUnited States of America

Listed2005

Employees186.0

CEOPhillip Chan

SectorHealthcare

IndustryMedical - Devices

Websitecytosorbents.com

FilingsSEC EDGAR

Questions, answered.

What is Cytosorbents's market cap?: Cytosorbents (CTSO) has a market capitalization of $23.4M and trades on NASDAQ.
Who are Cytosorbents's competitors?: Cytosorbents's key competitors include Baxter International (Vantive), LivaNova PLC Ordinary Shares, TransMedics Group, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Cytosorbents partner with?: Cytosorbents's notable partners include Fresenius Medical Care AG, B. Braun Avitum AG, Terumo Cardiovascular Group, and others.
Where is Cytosorbents headquartered?: Cytosorbents is headquartered in United States of America and employs approximately 186 people. It has been publicly traded since 2005.